• 首页期刊简介编委会刊物订阅专栏专刊电子刊学术动态联系我们English
引用本文:杨卫华.依帕司他治疗中度非增生性糖尿病视网膜病变[J].中国现代应用药学,2015,32(1):107-110.
YANG Weihua.Clinical Efficacy of Epalrestat for Moderate Non-proliferative Diabetic Retinopathy[J].Chin J Mod Appl Pharm(中国现代应用药学),2015,32(1):107-110.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2863次   下载 1798 本文二维码信息
码上扫一扫!
分享到: 微信 更多
依帕司他治疗中度非增生性糖尿病视网膜病变
杨卫华
浙江省湖州师范学院附属第一医院眼科,浙江 湖州 313000
摘要:
目的 观察依帕司他片治疗中度非增生性糖尿病视网膜病变的疗效。方法 经荧光素钠眼底血管造影检查(fluorescein fundus angiography,FFA)确诊的中度非增生性糖尿病视网膜病变75例(124眼)随机分为2组。研究组39例(64眼)予依帕司他片口服3个月,对照组36例(60眼)予羟苯磺酸钙胶囊口服3个月。3个月后复查视力和FFA,记录并比较2组的治疗效果。结果 视力改善方面,研究组总有效率67.2%,对照组总有效率43.3%,2组比较差异有统计学意义(P<0.05)。FFA眼底情况检查方面,依帕司他总有效率82.8%,对照组总有效率63.3%,2组比较差异有统计学意义(P<0.05)。结论 依帕司他片治疗中度非增生性糖尿病视网膜病变较羟苯磺酸钙胶囊疗效更好。
关键词:  依帕司他  糖尿病视网膜病变  羟苯磺酸钙
DOI:
分类号:
基金项目:
Clinical Efficacy of Epalrestat for Moderate Non-proliferative Diabetic Retinopathy
YANG Weihua
Department of Ophthalmology, the First Affiliated Hospital of Huzhou Teachers College, Huzhou 313000, China
Abstract:
OBJECTIVE To observe the clinical efficacy of epalrestat for moderate non-proliferative diabetic retinopathy. METHODS Seventy-five patients(124 eyes) with moderate non-proliferative diabetic retinopathy were diagnosed by the fundus fluorescein angiography(FFA) and randomly divided into two groups. Thirty-nine cases (64 eyes) in the study group were given oral epalrestat tablets at a dose of 50 mg three time a day for 3 months, and 36 cases (60 eyes) in the control group were given oral calcium dobesilate capsules at a dose of 0.5 g three times a day for 3 months. After 3 months the treatment effect of the two groups were compared with visual acuity and FFA examination. RESULTS The study group had a total effectiveness of 67.2% in the improvement of visual acuity, whereas the control group was 43.3%, and there was significant difference between the two groups(P<0.05). In the aspect of FFA fundus examination, epalrestat’s total effectiveness was 82.8% , while the total effectiveness of the control group was 63.3%, and there was significant difference between the two groups(P<0.05). CONCLUSION The efficacy of epalrestat tablets for the treatment of moderate non-proliferative diabetic retinopathy is better than calcium dobesilate capsules.
Key words:  epalrestat  diabetic retinopathy  calcium dobesilate
扫一扫关注本刊微信